I am physician-scientist invested in improving cardiovascular health among those with kidney disease. Soon after graduating from University of Antioquia Medical School (Colombia), I worked as a general practitioner directing programs for non-communicable diseases with a special focus on cardiovascular disease prevention. I then joined the Harvard Medical School’s Master of Medical Science in Clinical Investigation Class of 2018. During my master’s program, I spent two years at the TIMI study group investigating cardiovascular disease (CVD) in chronic kidney disease (CKD) and worked as a medical reviewer for the safety desk. Upon graduation, I joined the Mc Causland Lab at the Renal Division of Brigham and Women's Hospital, extending my research on CVD in CKD to end-stage renal disease and hemodialysis. My research encompasses observational studies looking at predictors of intradialytic hypotension with a special focus on neurohormonal axes, studies evaluating risk factors for progression of CKD and CVD, the use of point-of-care devices in hemodialysis and clinical trials assessing interventions to prevent intradialytic hypotension. I am interested in conducting clinical trials in CKD and ESRD and I was member of the Clinical Endpoint Center (CEC) at Brigham and Women’s Hospital where I participated adjudicating clinical events for NIH- and industry-sponsored phase 3 trials. I hope to become the next cardiorenal trialist, bridging the gap between the kidney and the heart.